

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Gardella et al.	Confirmation No.:	1482
Serial No.:	10/564,744	Art Unit:	1654
Filed:	March 3, 2006	Examiner:	A. Gupta
Customer No.:	21559		
Title:	CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONE (PTH) ANALOGS		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications.

EP 0 464 533 is written in the German language. This publication is related to U.S. Patent No. 7,253,264, which is in the English language and is listed in the enclosed Form PTO-1449.

EP 0 783 522 and WO 96/010041 are related applications and are written in the German language. Both EP 0 783 522 and U.S. Patent No. 6,030,790 are national stage applications of WO 96/010041. Accordingly, U.S. Patent No. 6,030,790 is provided as an English translation of EP 0 783 522 and WO 96/010041, and is listed in the enclosed Form PTO-1449.

JP 58-96052 and JP 59-204159 are written in the Japanese language. English abstracts are accordingly provided.

JP 5-32696 is also written in the Japanese language. This publication is related to U.S. Patent No. 5,393,869, which is in the English language and is listed in the enclosed Form PTO-1449.

JP 9-157294 is also written in the Japanese language. This publication is related to EP 0 748 817, which is in the English language and is listed in the enclosed Form PTO-1449. A copy of EP 0 748 817 is accordingly provided.

PCT Publication No. WO 93/011257 is written in the German language. U.S. Patent No. 5,854,004, the U.S. National stage of the corresponding PCT Application, is written in the English language and is provided as a translation of PCT Publication No. WO 93/011257. U.S. Patent No. 5,854,004 is listed in the enclosed Form PTO-1449.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office action on the merits, but before the mailing of a final Office action or a Notice of Allowance. Please charge Deposit Account No. 03-2095 in the amount of \$180.00 in payment of the fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,



*J. Elbing C. Keeler*  
Reg. No.  
57,727 R.

Date: March 27, 2010

Karen L. Elbing, Ph.D.  
Reg. No. 35,238

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045